{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:49:02Z","timestamp":1782362942294,"version":"3.54.5"},"reference-count":30,"publisher":"Media Sphere Publishing House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:p>Diabetic macular edema (DME) is a degenerative disease of the macular area in diabetes mellitus and can lead to vision loss, disability, and significantly reduced quality of life. Faricimab is the only bispecific antibody for DME therapy that targets two pathogenic pathways (Ang-2 and VEGF-A). Purpose. This study comparatively evaluates the clinical and economic feasibility of faricimab and other angiogenesis inhibitors in patients with DME. Material and methods. This article analyzed literature on the efficacy and safety of intravitreal injections (IVI) of ranibizumab 0.5 mg, aflibercept 2 mg, and faricimab 6 mg. A model of medical care was developed for patients with DME receiving anti-angiogenic therapy. Pharmacoeconomic analysis was performed using cost minimization and budget impact analysis (BIA) methods. Modeling time horizon was 2 years. The research was performed from the perspective of the healthcare system of the Russian Federation. Results. The efficacy and safety of faricimab in a personalized regimen (up to one IVI in 16 weeks) are comparable to those of aflibercept and ranibizumab, administered in various regimens. The use of faricimab is associated with the lowest number of IVIs. Over 2 years, the maximum costs of drug therapy were associated with the use of ranibizumab (about 914 thousand rubles), while the minimum costs were associated with the use of faricimab (614 thousand rubles). The reduction in inpatient care costs with faricimab therapy was 36% compared to aflibercept (216 and 201 thousand rubles in inpatient and day hospitals, respectively) and 82% compared to ranibizumab (486 and 451 thousand rubles in inpatient and day hospitals, respectively). BIA demonstrated that the use of faricimab will reduce the economic burden on the healthcare system by 11.3 billion rubles (9.8%) over 2 years. Conclusion. The use of faricimab is a cost-effective approach to treatment of adult patients with DME in Russia.<\/jats:p>","DOI":"10.17116\/oftalma2024140021112","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:57:10Z","timestamp":1715680630000},"page":"112","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacoeconomic analysis of anti-angiogenic drugs for diabetic macular edema"],"prefix":"10.17116","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-1120","authenticated-orcid":false,"given":"I.S.","family":"Krysanov","sequence":"first","affiliation":[{"name":"Russian University of Medicine","place":["Moscow, Russia"]},{"name":"Medical Institute of Continuing Education of the BIOTECH University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5621-5700","authenticated-orcid":false,"given":"D.L.","family":"Klabukova","sequence":"additional","affiliation":[{"name":"Russian University of Medicine","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0547-2088","authenticated-orcid":false,"given":"V.S.","family":"Krysanova","sequence":"additional","affiliation":[{"name":"Medical Institute of Continuing Education of the BIOTECH University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4822-7226","authenticated-orcid":false,"given":"V.Yu.","family":"Ermakova","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]},{"name":"OOO Institute of Clinical and Economic Expertise and Pharmacoeconomics","place":["Mytishchi, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma2024140021112-1","unstructured":"Haller JA, Schachat AP. Update on the pathophisiology, molecular biology, and treatment of macular edema. Adv Stud Ophthalmol. 2007;4(7):178-190"},{"key":"key-10.17116\/oftalma2024140021112-2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.9.2653"},{"key":"key-10.17116\/oftalma2024140021112-3","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.337"},{"key":"key-10.17116\/oftalma2024140021112-4","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021. Accessed 23.07.2022.  https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf"},{"key":"key-10.17116\/oftalma2024140021112-5","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70113-X"},{"key":"key-10.17116\/oftalma2024140021112-6","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2021137011123"},{"key":"key-10.17116\/oftalma2024140021112-7","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0317-y"},{"key":"key-10.17116\/oftalma2024140021112-8","unstructured":"International Council of Ophthalmology. Guidelines for Diabetic Eye Care. ICO; 2017;40"},{"key":"key-10.17116\/oftalma2024140021112-9","doi-asserted-by":"publisher","DOI":"10.1159\/000458539"},{"key":"key-10.17116\/oftalma2024140021112-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.025"},{"key":"key-10.17116\/oftalma2024140021112-11","unstructured":"Klinicheskie rekomendatsii. Sakharnyi diabet: retinopatiya diabeticheskaya, makulyarnyi otek diabeticheskii. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2023 [Clinical recommendations. Diabetes mellitus: diabetic retinopathy, diabetic macular edema. Ministry of Health of the Russian Federation, 2023]. Accessed 10.05.23. (In Russ.). https:\/\/cr.minzdrav.gov.ru\/recomend\/115_2"},{"key":"key-10.17116\/oftalma2024140021112-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.03.003"},{"key":"key-10.17116\/oftalma2024140021112-13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023"},{"key":"key-10.17116\/oftalma2024140021112-14","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.393"},{"key":"key-10.17116\/oftalma2024140021112-15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.01.004"},{"key":"key-10.17116\/oftalma2024140021112-16","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000849"},{"key":"key-10.17116\/oftalma2024140021112-17","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2021137021114"},{"key":"key-10.17116\/oftalma2024140021112-18","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0579-0"},{"key":"key-10.17116\/oftalma2024140021112-19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"key-10.17116\/oftalma2024140021112-20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"key-10.17116\/oftalma2024140021112-21","unstructured":"Metodicheskie rekomendatsii po provedeniyu sravnitel\u2019noi kliniko-ekonomicheskoi otsenki lekarstvennogo preparata (novaya redaktsiya) [Methodological recommendations for conducting a comparative clinical and economic assessment of a medicinal product (new edition)]. M.: FSBI \u00abCenter for Healthcare Quality Assessment and Control\u00bb of the Ministry of Health of Russia; 2018. (In Russ.)"},{"key":"key-10.17116\/oftalma2024140021112-22","unstructured":"Gosudarstvennyi reestr predel\u2019nykh otpusknykh tsen [State register of maximum selling prices]. Accessed 25.08.22. (In Russ.). https:\/\/grls.rosminzdrav.ru\/PriceLims.aspx"},{"key":"key-10.17116\/oftalma2024140021112-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.04.003"},{"key":"key-10.17116\/oftalma2024140021112-24","unstructured":"Metodicheskie rekomendatsii po raschetu zatrat pri provedenii kliniko-ekonomicheskikh issledovanii lekarstvennykh preparatov [Methodological recommendations for calculating costs when conducting clinical and economic studies of drugs]. M.: FSBI \u00abCenter for Healthcare Quality Assessment and Control\u00bb of the Ministry of Health of Russia; 2017. (In Russ.)"},{"key":"key-10.17116\/oftalma2024140021112-25","unstructured":"Programma gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2022 god i na planovyi period 2023 i 2024 godov [Program of state guarantees of free medical care to citizens for 2022 and for the planning period of 2023 and 2024]. Government of the Russian Federation; 2021. (In Russ.)"},{"key":"key-10.17116\/oftalma2024140021112-26","unstructured":"Metodicheskie rekomendacii po sposobam oplaty medicinskoj pomoshchi za schet sredstv obyazatel\u2019nogo medicinskogo strahovaniya. Protokol zasedaniya chlenov rabochej gruppy ot 26 yanvarya 2022 g. \u211666\/11\/1 [Methodological recommendations on methods of paying for medical care using funds from compulsory health insurance. Minutes of the meeting of the working group members dated January 26, 2022 No. 66\/11\/1]. Ministry of Health of the Russian Federation, Federal Compulsory Medical Insurance Fund. (In Russ.)"},{"key":"key-10.17116\/oftalma2024140021112-27","unstructured":"Metodicheskie rekomendatsii po otsenke vliyaniya na byudzhet v ramkakh realizatsii Programmy gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi (novaya redaktsiya) [Methodological recommendations for assessing the impact on the budget within the framework of the implementation of the Program of State Guarantees of Free Medical Care to Citizens (new edition)]. Moscow: FSBI \u00abCenter for Healthcare Quality Assessment and Control\u00bb of the Ministry of Health of Russia; 2018. (In Russ.)"},{"key":"key-10.17116\/oftalma2024140021112-28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5790"},{"key":"key-10.17116\/oftalma2024140021112-29","unstructured":"World Health Organization, International Agency for the Prevention of Blindness. Strategic Plan for Vision 2020: The Right to Sight. Geneva: World Health Organizaton; 2003. Accessed 23.07.22.  https:\/\/www.who.int\/blindness\/Vision2020_report.pdf"},{"key":"key-10.17116\/oftalma2024140021112-30","unstructured":"Faricimab for treating wet age-related macular degeneration. Technology appraisal guidance. Published: 29 June 2022. National Institute for Health and Clinical Excellence, 2022. Accessed 14.07.22.  https:\/\/www.nice.org.uk\/guidance\/ta800"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T08:40:32Z","timestamp":1745397632000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2024\/2\/10042465X2024021112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5,14]]}},"alternative-id":["10.17116\/oftalma2024140021112"],"URL":"https:\/\/doi.org\/10.17116\/oftalma2024140021112","relation":{},"ISSN":["0042-465X"],"issn-type":[{"value":"0042-465X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}